Drug Trial Radar · NCT06619561
A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
Last checked: Nov 20, 2026Latest source record: Dec 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
48
Planned (sponsor's estimate)
Start
Nov 21, 2024
Primary completion
Oct 2029
Study completion Oct 2029
Sponsor
- Lead sponsor
- Deciphera Pharmaceuticals, LLCIndustry
- Sponsor type
- Industry
- First posted
- Oct 1, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine if vimseltinib is safe, tolerable and works effectively to treat adults with active moderate to severe cGVHD. Participants will be treated with vimseltinib in 28-day treatment cycles for approximately 2 years.
Conditions
- Chronic Graft-Versus-Host Disease (cGVHD)
Interventions
VimseltinibDrug
Administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Dose-Limiting Toxicities (DLTs)Time frame: Cycle 1 (28 Days)
- Number of Participants with Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs)Time frame: Baseline to Study Completion (Estimated up to 24 months)
Locations
26 sites in 1 country. Site status is shown where the registry gives one.
City of Hope National Medical Center
Duarte, California · Recruiting
Ronald Regan UCLA Medical Center
Los Angeles, California · Recruiting
University of California Irvine Health
Orange, California · Recruiting
AdventHealth Orlando
Orlando, Florida · Recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
Emory University Winship Cancer Institute
Atlanta, Georgia · Recruiting
University of Illinois Medical Center - Hematology & Oncology
Chicago, Illinois · Recruiting
University of Kansas Cancer Center-Westwood
Westwood, Kansas · Recruiting
University of Kentucky Markey Cancer Center
Lexington, Kentucky · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
Henry Ford Cancer Institute
Detroit, Michigan · Recruiting
Washington University School of Medicine - Siteman Cancer Center
St Louis, Missouri · Recruiting
Levine Cancer Institute
Charlotte, North Carolina · Recruiting
Duke University Hospital
Durham, North Carolina · Recruiting
Oncology Hematology Care Clinical Trials, LLC
Cincinnati, Ohio · Recruiting
Cleveland Clinic
Cleveland, Ohio · Recruiting
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio · Recruiting
Oregon Health and Science University
Portland, Oregon · Recruiting
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania · Recruiting
Avera Cancer Institute
Sioux Falls, South Dakota · Recruiting
Tristar Bone Marrow Transplant
Nashville, Tennessee · Recruiting
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee · Recruiting
St. David's South Austin Medical Center
Austin, Texas · Recruiting
UT Southwestern Medical Center
Dallas, Texas · Recruiting
Intermountain Health
Salt Lake City, Utah · Recruiting
Virginia Commonwealth University
Richmond, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.